Table 2 Breakdown of test samples used to evaluate sensitivity and specificity of three technologies
Product | Manufacturer | Field samples | Additional samples | Total | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
Accra | Bolga | HO | Kumasi | Takoradi | Counter–FEIT | Authentic | Stressed | |||
Artemetheter-Lumefantrine tablets, 20/120 mg | Ipcaa | 0 | 1 | 0 | 3 | 1 | 0 | 0 | 0 | 5 |
Lumerax (Artemether + Lumefantrine tablets, 40/240 mg) | Ipca | 2 | 0 | 0 | 4 | 5 | 0 | 0 | 0 | 11 |
Coartem (Artemether + Lumefantrine tablets, 20/120 mg) | Novartis | 2 | 4 | 3 | 3 | 2 | 3 | 0 | 0 | 17 |
Coartem dispersible (Artemether + Lumefantrine tablets, 20/120 mg) | Novartis | 4 | 0 | 3 | 0 | 3 | 0 | 3 | 1 | 14 |
Winthrop (Artesunate + Amodiaquine tablets, 50/135 mg) | Sanofi-Aventis | 8 | 5 | 1 | 1 | 10 | 0 | 3 | 1 | 29 |
Winthrop (Artesunate + Amodiaquine tablets, 100/270 mg) | Sanofi-Aventis | 1 | 3 | 1 | 0 | 3 | 0 | 0 | 0 | 8 |
Total | 17 | 13 | 8 | 11 | 24 | 3 | 6 | 2 | 84 | |